Point-counterpoint: Are We Overtreating Patients with Mild Ulcerative Colitis?

Overview

Journal J Crohns Colitis

Publisher Oxford University Press

Date 2013 Aug 14

PMID 23938211

Citations 1

Authors

Akbar K Waljee

Ryan W Stidham

Peter D R Higgins

Sandeep Vijan

Sameer D Saini

Affiliations

Soon will be listed here.

Citing Articles

Defining Comprehensive Disease Control for Use as a Treatment Target for Ulcerative Colitis in Clinical Practice: International Delphi Consensus Recommendations.

Schreiber S, Danese S, Dignass A, Domenech E, Fantini M, Ferrante M J Crohns Colitis. 2023; 18(1):91-105.

PMID: 37586038 PMC: 10821705. DOI: 10.1093/ecco-jcc/jjad130.

References

Rutter M, Saunders B, Wilkinson K, Rumbles S, Schofield G, Kamm M . Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology. 2004; 126(2):451-9. DOI: 10.1053/j.gastro.2003.11.010. View

Bergeron V, Vienne A, Sokol H, Seksik P, Nion-Larmurier I, Ruskone-Fourmestraux A . Risk factors for neoplasia in inflammatory bowel disease patients with pancolitis. Am J Gastroenterol. 2010; 105(11):2405-11. DOI: 10.1038/ajg.2010.248. View

Kane S, Cohen R, Aikens J, Hanauer S . Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. Am J Gastroenterol. 2001; 96(10):2929-33. DOI: 10.1111/j.1572-0241.2001.04683.x. View

van Staa T, Travis S, Leufkens H, Logan R . 5-aminosalicylic acids and the risk of renal disease: a large British epidemiologic study. Gastroenterology. 2004; 126(7):1733-9. DOI: 10.1053/j.gastro.2004.03.016. View

Karlen P, Lofberg R, Brostrom O, Leijonmarck C, Hellers G, Persson P . Increased risk of cancer in ulcerative colitis: a population-based cohort study. Am J Gastroenterol. 1999; 94(4):1047-52. DOI: 10.1111/j.1572-0241.1999.01012.x. View

Gupta R, Harpaz N, Itzkowitz S, Hossain S, Matula S, Kornbluth A . Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. Gastroenterology. 2007; 133(4):1099-105. PMC: 2175077. DOI: 10.1053/j.gastro.2007.08.001. View

Romkens T, Kampschreur M, Drenth J, van Oijen M, de Jong D . High mucosal healing rates in 5-ASA-treated ulcerative colitis patients: results of a meta-analysis of clinical trials. Inflamm Bowel Dis. 2012; 18(11):2190-8. DOI: 10.1002/ibd.22939. View

Kane S, Huo D, Aikens J, Hanauer S . Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am J Med. 2003; 114(1):39-43. DOI: 10.1016/s0002-9343(02)01383-9. View

Bernstein C, Blanchard J, Kliewer E, Wajda A . Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer. 2001; 91(4):854-62. DOI: 10.1002/1097-0142(20010215)91:4<854::aid-cncr1073>3.0.co;2-z. View

10.

Kornbluth A, Sachar D . Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2010; 105(3):501-23. DOI: 10.1038/ajg.2009.727. View

11.

Matza L, Boye K, Yurgin N, Brewster-Jordan J, Mannix S, Shorr J . Utilities and disutilities for type 2 diabetes treatment-related attributes. Qual Life Res. 2007; 16(7):1251-65. DOI: 10.1007/s11136-007-9226-0. View

12.

Bernstein C, Nugent Z, Blanchard J . 5-aminosalicylate is not chemoprophylactic for colorectal cancer in IBD: a population based study. Am J Gastroenterol. 2011; 106(4):731-6. DOI: 10.1038/ajg.2011.50. View

13.

Khan N, Abbas A, Bazzano L, Koleva Y, Krousel-Wood M . Long-term oral mesalazine adherence and the risk of disease flare in ulcerative colitis: nationwide 10-year retrospective cohort from the veterans affairs healthcare system. Aliment Pharmacol Ther. 2012; 36(8):755-64. DOI: 10.1111/apt.12013. View

14.

Robinson M, Hanauer S, Hoop R, Zbrozek A, Wilkinson C . Mesalamine capsules enhance the quality of life for patients with ulcerative colitis. Aliment Pharmacol Ther. 1994; 8(1):27-34. DOI: 10.1111/j.1365-2036.1994.tb00157.x. View

15.

Hoie O, Wolters F, Riis L, Bernklev T, Aamodt G, Clofent J . Low colectomy rates in ulcerative colitis in an unselected European cohort followed for 10 years. Gastroenterology. 2007; 132(2):507-15. DOI: 10.1053/j.gastro.2006.11.015. View

16.

Waljee A, Higgins P, Waljee J, Tujios S, Saxena A, Brown L . Perceived and actual quality of life with ulcerative colitis: a comparison of medically and surgically treated patients. Am J Gastroenterol. 2011; 106(4):794-9. PMC: 4429766. DOI: 10.1038/ajg.2011.39. View

17.

Velayos F, Terdiman J, Walsh J . Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am J Gastroenterol. 2005; 100(6):1345-53. DOI: 10.1111/j.1572-0241.2005.41442.x. View

18.

Levy R, Feld A . Increasing patient adherence to gastroenterology treatment and prevention regimens. Am J Gastroenterol. 1999; 94(7):1733-42. DOI: 10.1111/j.1572-0241.1999.01200.x. View

19.

Gisbert J, Gonzalez-Lama Y, Mate J . 5-Aminosalicylates and renal function in inflammatory bowel disease: a systematic review. Inflamm Bowel Dis. 2007; 13(5):629-38. DOI: 10.1002/ibd.20099. View

20.

Nguyen G, Gulamhusein A, Bernstein C . 5-aminosalicylic acid is not protective against colorectal cancer in inflammatory bowel disease: a meta-analysis of non-referral populations. Am J Gastroenterol. 2012; 107(9):1298-304. DOI: 10.1038/ajg.2012.198. View